keyword
MENU ▼
Read by QxMD icon Read
search

pertuzumab not cost-effective

keyword
https://www.readbyqxmd.com/read/28840424/economic-evaluation-of-sequencing-strategies-in-her2-positive-metastatic-breast-cancer-in-mexico-a-contrast-between-public-and-private-payer-perspectives
#1
Vakaramoko Diaby, Askal Ayalew Ali, Krystal J Williams, Kyrian Ezendu, Enrique Soto-Perez-de-Celis, Yanin Chavarri-Guerra, Gilberto de Lima Lopes
PURPOSE: Breast cancer is the most common malignancy among women in Mexico. A large proportion of Mexican patients present with advanced disease, and 25% have HER2-positive tumors. We performed a cost-effectiveness analysis of different sequencing strategies of HER2-targeted agents in Mexico according to various payer perspectives. METHODS: A Markov model was constructed to evaluate the cost-effectiveness of four different HER2-targeted treatment sequences among patients with HER2-positive metastatic breast cancer treated in Mexico according to three public and one private payer perspectives...
August 24, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28770452/pertuzumab-for-the-neoadjuvant-treatment-of-early-stage-her2-positive-breast-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#2
REVIEW
Hazel Squires, Abdullah Pandor, Praveen Thokala, John W Stevens, Eva Kaltenthaler, Mark Clowes, Robert Coleman, Lynda Wyld
As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer of pertuzumab (Perjeta(®); Roche Products Limited) to submit evidence of its clinical and cost- effectiveness for the neoadjuvant treatment of women with high-risk, early-stage, HER2-positive breast cancer when used in combination with trastuzumab and chemotherapy. High-risk women included those with locally advanced (including inflammatory) breast cancer and women with high-risk early-stage breast cancer (classified as T2/3 or N1)...
August 2, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/25494903/milestones-in-breast-cancer-treatment
#3
Stefano Zurrida, Umberto Veronesi
Modern treatment started in the 1880s with Halsted's mastectomy. The next milestone-a century later-was breast-conserving surgery, with equivalent survival but better esthetic outcomes than mastectomy. Sentinel node biopsy, introduced in the 1990s, was a milestone that permitted avoidance of axillary dissection if the sentinel node was disease-free. Chemotherapy was established for early breast cancer in the 1980s and its efficacy continues to improve; however side effects remain a concern, particularly since chemotherapy does not benefit most patients...
January 2015: Breast Journal
https://www.readbyqxmd.com/read/25347449/cost-effectiveness-analysis-of-neoadjuvant-pertuzumab-and-trastuzumab-therapy-for-locally-advanced-inflammatory-or-early-her2-positive-breast-cancer-in-canada
#4
C L Attard, A N Pepper, S T Brown, M F Thompson, P-O Thuresson, S Yunger, S Dent, A H Paterson, G A Wells
OBJECTIVE: The NeoSphere trial demonstrated that the addition of pertuzumab to trastuzumab and docetaxel for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer (eBC) resulted in a significant improvement in pathological complete response (pCR). Furthermore, the TRYPHAENA trial supported the benefit of neoadjuvant dual anti-HER2 therapy. Survival data from these trials is not yet available; however, other studies have demonstrated a correlation between pCR and improved event-free survival (EFS) and overall survival (OS) in this patient population...
March 2015: Journal of Medical Economics
https://www.readbyqxmd.com/read/25138171/pertuzumab-in-combination-with-trastuzumab-and-docetaxel-for-the-treatment-of-her2-positive-metastatic-or-locally-recurrent-unresectable-breast-cancer
#5
REVIEW
Nigel Fleeman, Adrian Bagust, Sophie Beale, Kerry Dwan, Rumona Dickson, Chris Proudlove, Yenal Dundar
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of pertuzumab (Roche) to submit evidence for the clinical and cost effectiveness of pertuzumab + trastuzumab + docetaxel for the treatment of human epidermal growth factor receptor 2-positive (HER2+) metastatic or locally recurrent unresectable breast cancer in accordance with the Institute's Single Technology Appraisal (STA) process. The Liverpool Reviews and Implementation Group (LRiG) at the University of Liverpool was commissioned to act as the Evidence Review Group (ERG)...
January 2015: PharmacoEconomics
https://www.readbyqxmd.com/read/23988598/pertuzumab-for-the-treatment-of-human-epidermal-growth-factor-receptor-type-2-positive-metastatic-breast-cancer
#6
REVIEW
Clement Chung, Masha S H Lam
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, safety, and administration of pertuzumab in patients with metastatic human epidermal growth factor receptor type 2 (HER2)-positive breast cancer are reviewed. SUMMARY: Disease progression in HER2-positive breast cancer is often due to resistance to or a lack of efficacy of trastuzumab-based anti-HER2 therapy. Pertuzumab is the first humanized monoclonal antibody in a new class of drugs, the HER dimerization inhibitors, approved by the Food and Drug Administration for the first-line treatment of patients with metastatic HER2-positive breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease...
September 15, 2013: American Journal of Health-system Pharmacy: AJHP
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"